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Proteotoxins such as ricin, abrin, botulinum neurotoxins type A and B (BoNT/A, BoNT/B) and 
staphylococcal enterotoxin B (SEB) are regarded as potential biological warfare agents which could be 
used for bioterrorism attacks on the food chain. In this study we used a novel immunisation strategy to 
generate high-affinity monoclonal and polyclonal antibodies against native ricin, BoNT/A, and BoNT/B. 
The antibodies were used along with antibodies against SEB and abrin to establish a highly sensitive 
magnetic and fluorescent multiplex bead array with excellent sensitivities between 2 ng/L and 546 
ng/L from a minimal sample volume of 50 mL. The assay was validated using 20 different related 
analytes and the assay precision was determined. Advancing the existing bead array technology, 
the novel magnetic and fluorescent microbeads proved amenable to enrichment procedures, by further 
increasing sensitivity to 0.3–85 ng/L, starting from a sample volume of 500 mL. Furthermore, the 
method was successfully applied for the simultaneous identification of the target toxins spiked into 
complex food matrices like milk, baby food and yoghurt. On the basis of our results, the assay appears 





Ever since the alleged preparation of ricin by terrorist groups and the ricin findings in the US postal 
system in 2003, it has become evident that there is an urgent need to develop rapid, sensitive and 
specific detection systems for toxins. High molecular-weight proteotoxins such as ricin, abrin, 
botulinum neurotoxins (BoNT) and staphylococcal enterotoxin B (SEB) are regarded as potential 
biological warfare agents. They could be used for small-scale attacks on the basis of their availability, 
ease of preparation, their high toxicity and/or the lack of medical countermeasures. One likely scenario 
focuses on toxins as water or food contaminants, especially in food that is not further heated before 
consumption.1,2  
 
Ricin and abrin are highly toxic plant lectins, derived from the seeds of the ornamental plants Ricinus 
communis and Abrus precatorius, respectively. Both lectins are prototypic A-B toxins which effectively 
inhibit protein synthesis by depurinating the 28S ribosomal RNA. For ricin, the oral toxicity in humans 
expressed as half-maximal lethal dose (LD50) is estimated to be 1–20 mg/kg body weight and for 
abrin 0.1–1 mg/kg body weight.3,4 Both R. communis and A. precatorius seeds contain a second toxic 
lectin named R. communis agglutinin and A. precatorius agglutinin, which are highly homologous 
(around 90% sequence identity for ricin and R. communis agglutinin) to 
ricin or abrin, respectively, but are less toxic.5–7  
 
The rod-shaped bacterium Clostridium botulinum produces seven different serotypes of BoNT. 
Serotypes BoNT/A, BoNT/B, BoNT/E and BoNT/F have been shown to cause botulism in humans. 
Botulinumneurotoxins act at the neuromuscular junction 
  
of cholinergic neurons to induce flaccid paralysis by interfering with components of the vesicle fusion 
machinery. Exceedingly small quantities of toxin are sufficient for poisoning: the oral lethal dose of 
botulinum toxin for man is approximately 1 mg/kg.8 Staphylococcal enterotoxin B (SEB) is one of 
several heatstable enterotoxins produced by the Gram-positive bacterium Staphylococcus aureus, 
which is known as a major human pathogen. The toxin functions both as potent gastrointestinal toxin, 
as well as a superantigen that stimulates non-specific T-cell proliferation and cytokine release. On the 
basis of its functional activity SEB has been classified as an incapacitating agent by the Centers of 
Disease Control and Prevention (Atlanta, GA, USA). The minimum level of toxin causing 
gastroenteritis in humans is approximately 1 ng/g of food.1,9  
 
From a diagnostic point of view, toxins are a challenging group of agents as they may act in the 
absence of the producing organism and its genetic information. Therefore, their detection cannot – as 
in the case of viruses and bacteria – rely on nucleic acid-based methods. Rather, the toxin itself has to 
be detected either by immunological, mass spectrometric or functional assays.10–12 Immunological 
techniques offer the advantages of being highly specific, selective and sensitive, and furthermore can 
be implemented into field-deployable devices. For the sensitive immunological detection of toxins, 
specific antibodies are required which bind their target protein with high affinity. The generation of 
high-affinity antibodies specific for native toxins is difficult, however, since in most cases animals 
cannot be immunised with the active molecules, e.g. the toxic dose of botulinum toxins is lower than 
the immunogenic dose. Inactivation of native toxins under at least partial maintenance of 3-
dimensional (3-D) epitopes is necessary in order to prevent the poisoning of animals and to 
simultaneously enable generation of antibodies against native 3-D structures. To this end, different 
approaches have been described, for example, immunisation using immunogenic peptides derived 
from the toxins, immunisation with recombinant sub-chains or fragments of toxins, immunisation with 
toxoid (formaldehyde-treated or heat-inactivated toxin) or with DNA.13–15 These methods are both 
time-consuming and, to a variable degree, labour-intensive. Hence, in this study we have tested a 
novel immunisation strategy for ricin, BoNT/A and BoNT/B: we covalently immobilised the native toxins 
onto microbeads in order to reduce their toxicity in vivo.  
 
Most laboratory tests for the afore-mentioned toxins are performed in a single test format using 
sandwich enzyme linked immunosorbent assay (ELISA) techniques.14,16–20 It is often desirable, 
however, to monitor multiple toxins simultaneously in order to reduce materials used, as well as cost 
and effort.21 Different techniques for multiplex toxin detection have been reported in recent years, and 
some of them have already been included into field-deployable devices (see Supplementary Table 
S1†). Most of the multiple analyte assays or biosensors suffer from a lack of sensitivity, as they detect 
ricin, SEB or BoNT in the mid mg/L-range. Very few multiplex devices have been shown to deliver 
sensitive results from complex food matrices.22–24 Among the multiplex platforms described, the 
suspension array technology, also called Luminex xMAP technology (Luminex Corp., Austin, USA), is 
of interest for the broad-range use in standard laboratories, as it is commercially available. The 
conventional suspension array technology uses polystyrene microspheres which are embedded with 
precise ratios of red and infrared fluorescent dyes, thus yielding an array of 100 bead sets which are 
spectrally unique and can be distinguished by flow cytometry. The assay principle is similar to a 
sandwich ELISA: differently coloured microbeads are covalently coupled to antibodies specific for 
different antigens, thus allowing the simultaneous detection of multiple antigens from a minimal 
sample volume of 50 mL. The bound analytes are detected via biotinylated secondary antibodies and 
the fluorescent reporter streptavidin-phycoerythrin. The Luminex flow cytometer addresses (i) the 
fluorescent signature of the bead set and (ii) the intensity of the reporter signal per bead set.  
 
With respect to detection of biothreat agents, the conventional suspension array technology has been 
described for the detection of certain relevant agents.25–29 In this report, we describe the application 
of newly available fluorescent microbeads, which are also magnetic. The spectrally unique, magnetic 
beads have a diameter of 6.5 mmand a surface area of 133 μm2 and, similar to the conventional 
polystyrene beads, 100 different bead sets are available. Magnetic beads offer the major advantage of 
being easily separated from complex food matrices and are thus amenable to immunomagnetic 
enrichment procedures.  
 
In the current work, we applied a novel immunisation strategy to develop monoclonal antibodies (mAb) 
and polyclonal antibodies (pAb) specific for native ricin, BoNT/A, BoNT/B in different experimental 
animals. The antibodies were used along with antibodies specific for SEB and abrin to develop a 5-
plex fluorescent magnetic suspension array with sensitivities in the 
low ng/L-range from a minimal sample volume of 50 mL. Enrichment of toxins from a larger sample 
volume (500 mL) was possible and resulted in even increased sensitivities for all five toxins. Finally, 
  
we show that the multiplex assay can be used to simultaneously detect ricin, BoNT/A, BoNT/B, abrin 






Toxins and bacterial strains  
 
Ricin (purity 98%, kindly provided by U. Pfüller, University Witten/Herdecke, Germany) was purified 
along with R. communis agglutinin from the seeds of R. communis, according to standard 
procedures.30 Purified ricin A- and ricin B-chains, different lectins (Helix pomatia agglutinin, Dolichos 
biflors agglutinin) and SEB were obtained from Sigma-Aldrich (Munich, Germany). 
Both the purified 150 kDa neurotoxins and the neurotoxin protein complexes of botulinum toxin A 
(BoNT/A, derived from Hall strain), botulinum toxin B (BoNT/B, from Okra strain), botulinum toxin E 
(BoNT/E, from Alaska strain) and botulinum toxin F (BoNT/F, from Langeland strain) were obtained 
from Metabiologics (Madison, WI, USA). Abrin and staphylococcal enterotoxins were from Toxin 
Technology (Sarasota, FL, USA) and Sigma-Aldrich (Munich, Germany). For validation of the multiplex 
suspension array we used bacterial cell culture supernatants from the following strains: C. botulinum 
strain 2298 (serotype A, 62A), strain 2267 (serotypeA, CECT551), strain 1029 (serotype 
B,NCTC7273), strain 2625 (serotype E, CB-S21E), strain 2297 (serotype F, 83-4304), all kindly 
provided by F.Gessler (Göttingen, Germany). Appropriate safety measures were followed when 
handling toxins. Personal protective equipment was worn and toxins were handled under a class II 
vertical laminar flow cabinet (Heraeus Herasafe, Thermo Fisher Scientific, Waltham,MA,USA). Prior to 
disposal, toxin-containing solutions were treated with 5% sodium hydroxide. SEB-containing samples 
as well as consumables were autoclaved at 121 °C for 60 min.  
 
 
Inactivation of toxins for immunisation 
 
For immunisations using immobilised native toxins, ricin, BoNT/A, and BoNT/B were covalently 
coupled to tosyl-activated Dynabeads M-280 (size 2.8 mm; Invitrogen, Karlsruhe, Germany) using a 
modified coupling procedure. Briefly, 6.5 x 108 Dynabeads were washed twice with buffer A (0.1 M 
sodium-phosphate buffer, pH 7.4), resuspended in 100 mL toxin solution (concentration: 0.5 g/L for 
ricin and 0.05–0.2 g/L for BoNT/A or BoNT/B, in phosphate-buffered saline (PBS)) and were incubated 
for 20 h at 37 °C, under rotation. The toxin-beadsolution was washed twice with 800 mL buffer C (PBS 
containing 0.1% mouse serum, 0.1% rabbit serum or 0.1% ovalbumin, depending on the species to be 
immunised: mouse, rabbit or chicken) and reactive binding sites were blocked with 800 mL buffer D 
(0.2 M Tris containing 0.1% mouse serum, 0.1% rabbit serum or 0.1% ovalbumin, pH 8.5, 
respectively) for 4 h at 37 °C, under rotation. The toxin-beads were washed at least three times with 
800 mL buffer C until no free toxin was detectable in the supernatant via ELISA and stored in 500 mL 
buffer C at 4 °C. We have observed that, after prolonged storage at 4 °C (>15 months), free toxin 
becomes detectable in the supernatant. Therefore, we routinely use toxin-coupled beads for about 
6 months.  
 
In order to generate monoclonal (mAb) and polyclonal antibodies (pAb), we used covalently 
immobilised ricin, BoNT/A and BoNT/B to immunise mice, chickens and/or rabbits. For each toxin and 
each species separately, we tested the amount of immobilised toxin inducing a specific titer 
(exemplarily shown for rabbit RB77 in Supplementary Table S2 and Fig. S1†).  
 
As an alternative and conventional approach, toxins were inactivated using formaldehyde using 
standard procedures.31 
Briefly, BoNT/A and BoNT/B toxoids were prepared by adding 37% formaldehyde to the purified 
neurotoxin, resulting in a final concentration of 0.5% formaldehyde. This solution was kept for 21 days 








Generation of monoclonal antibodies  
 
BALB/c mice were bred under pathogen-free conditions at the Federal Institute for Risk Assessment 
(Berlin, Germany) and were used at the age of 8 weeks. In the case of ricin, three mice were 
immunised intraperitoneally (i.p.) with 5 mL ricin-beads, corresponding to 2.5 mg native ricin covalently 
coupled to the beads (this is approximately a 15-fold LD50 in mice) in complete Freund’s adjuvant 
(CFA, Sigma-Aldrich, Munich, Germany). Mice were boosted several times with increasing doses of 
the same antigen (up to 10 mL of ricin-beads, corresponding to 5 mg native ricin and a 30-fold LD50 
coupled to beads) i.p. in incomplete Freund’s adjuvants (IFA, Sigma-Aldrich, Munich, Germany) at 
four-week intervals. Subsequently, mice were 
boostered several times with up to 16 mg of free native ricin. Three days before fusion, 4–16 mg of 
native ricin were applied i.p. once per day (see Supplementary Table S3†). In the case of BoNT/A and 
BoNT/B immunisation of mice, 25 mg toxoid in CFA were applied for primary immunisation followed by 
up to 4 boosts using 50 mg toxoid in IFA. Once the mice showed a BoNT-specific titer, they were 
boosted with a 50-fold LD50 of native BoNT in IFA. On day -3, -2, and -1 before fusion, mice 
were injected i.p. with a 250-fold LD50 of native BoNT in PBS. In the case of SEB, which is less toxic 
than the above-mentioned toxins, BALB/c mice were immunised three times with 25–50 mg 
recombinant SEB (Toxin Technology, Sarasota, FL, USA) and boostered on day -3, -2 and -1 before 
fusion as above.  
 
Hybridomas were produced by fusing spleen cells from immunised mice with myeloma cells (P3-X63-
Ag8.653, American Type Culture Collection) at a ratio of 2 : 1 in polyethylene glycol 1500 (PEG, 
Roche Diagnostics, Mannheim, Germany) according to standard procedures.32 Cells were plated on 
BALB/c thymocytes as feeder cells in RPMI 1640 media containing 20% foetal calf serum, 50 mM 2-
mercaptoethanol, 50 U/mL recombinant murine IL-6, 1% glutamine, 5.8 mM azaserine and 100 mM 
hypoxanthine. Supernatants from all fusions were screened for specific antibodies using an indirect 
ELISA against the corresponding toxins on days 10–14, post-fusion. In a parallel approach, we also 
screened for functionally blocking ricin antibodies, similarly to Furukawa-Stoffer et al.33 In this case, 
fused cells were plated in RPMI 1640 media containing the supplements indicated above and 16 ng/L 
native ricin. Hybridomas surviving the ricin exposure were tested for neutralising capacity in a 
cytotoxicity assay. All positive hybridoma clones were subcloned at least once and stable subclones 
were tested for intracellular IgG production by flow cytometry.34 Immunoglobulins (IgG) were purified 
from hybridoma supernatants by means of HiTrap protein G-Sepharose column (GE Healthcare Life 
Science, Piscatawa, NJ, USA) and checked for purity using 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The concentration of purified 
antibodies was measured using the Bradford-Assay (Bio-Rad Laboratories, Munich, Germany). The 
isotype of monoclonal antibodies was determined using the IsoStrip mouse monoclonal antibody 
isotyping kit (Roche Applied Science, Mannheim, Germany). 
 
 
Production of polyclonal antibodies 
 
In order to generate rabbit polyclonal antibodies (pAb), rabbits were immunised first with bead-
immobilised BoNT/A and later on with free native BoNT/A using the following protocol: (i) several 
immunisations with 100 mL BoNT/A-beads (corresponding to 5 mg native BoNT/A coupled to beads; 
this is equivalent to a 500 000-fold LD50 in mice) subcutaneously (s.c.), either in CFA or later IFA; (ii) 
after detection of a specific titer, animals were further boosted s.c. with increasing doses of free native 
BoNT/A (up to 160 ng) in IFA. In the case of BoNT/B, immunisations were done similarly, except for 
the doses used for immunisations: (i) several immunisations with up to 30 mL BoNT/B-beads 
(corresponding to 15 mg native BoNT/B coupled to beads; this is equivalent to the 3 000 000-fold 
LD50 in mice) in CFA or IFA, respectively; (ii) up to 20 ng free native BoNT/B in IFA (see 
Supplementary Table S2 and Fig. S1†). Blood samples were collected 10–15 days after each 
immunisation and tested for specific antibodies using indirect ELISA against the corresponding toxins. 
IgG were purified from rabbit serum by means of protein G-Sepharose column as described above. 
 
For the generation of polyclonal chicken antibodies, animals were immunised by the following protocol: 
in the case of ricin, chickens were first immunised intramuscularly (i.m.) with 12 mL ricin-beads 
(corresponding to 6 mg native ricin coupled to beads) followed by several immunisations with up to 20 
mg free native ricin in IFA. For of BoNT/A and BoNT/B, immunisation started with 20 mL BoNT/A-
beads (corresponding to 1 mg native BoNT/A immobilised on beads) or 200 mL BoNT/B-beads 
(corresponding to 10 mg native BoNT/B coupled to beads) in CFA, respectively, and was increased up 
to 30 mg immobilised BoNT in IFA given i.m. Eggs were collected from days 10 to 20 post-
  
immunisation and polyclonal IgY were prepared from the egg yolk using fractionated PEG precipitation 
as described elsewhere.35  
 
 
Ricin cytotoxicity assay and test for functional blockade in vitro  
 
A cytotoxicity assay was used for determining the neutralising capacity of ricin-specific hybridoma 
supernatants and purified mAb, as described previously.36 Briefly, Vero cells (1 x 105 cells per mL, 
100 mL per well, American Type Culture Collection) were seeded in 96-well plates and incubated for 
18 h at 37 °C. On the next day, the cells were treated for 2 h either with ricin alone (final concentration 
of ricin 10 mg/L) or with a mixture of ricin and antibodies which have been pre-incubated separately 
for 1.5 h at 37 °C (final concentration of antibodies 75 mg/L to 0.6 mg/L). After washing, the treated 
cells were further incubated at 37 °C for 20 h. The viability of the Vero cells was quantified using the 
CellTiter96 Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI, USA). 
 
In order to compare the toxicity of free native ricin with ricin covalently immobilised on Dynabeads, we 
used a similar assay where serial dilutions of the free or immobilised toxin were tested in parallel. To 
quantify the amount of ricin immobilised on the beads we subtracted the amount of toxin that could be 
detected via sandwich ELISA in all washing solutions of the coupling reaction from the amount of toxin 





MaxiSorp microtiter plates (Nunc, Wiesbaden, Germany) were coated with antigen (500 mg/L, 50 mL 
per well) in PBS overnight at 4 °C and blocked with blocking buffer (PBS, 0.1% Tween 20, 2% 
skimmed milk (Merck, Darmstadt, Germany)) for 1 h. After washing, the antibody was added (10 mg/L 
in blocking buffer) for 1 h and was detected using horseradish peroxidase (HRP)-labelled goat anti-
mouse IgG, donkey antichicken IgG or goat anti-rabbit IgG, as appropriate (Dianova, Hamburg, 





MaxiSorp microtiter plates were coated with mAb (10 mg/L) in 50 mL PBS overnight at 4 °C and 
blocked with casein buffer (Diavita, Heidelberg, Germany) for 1 h at room temperature. Following 
washing, 50 mL of toxin was added in serial dilutions from 100 mg/L to 0.05 ng/L in assay buffer (PBS, 
0.1% bovine serum albumin (BSA; Sigma-Aldrich, Munich, Germany)) and incubated for 2 h at room 
temperature. The sandwich ELISA was developed by incubation with biotin-labelled secondary 
antibody diluted in casein buffer (1 h, room temperature), followed by washing and detection with 





Antigens were separated by 12% SDS-PAGE under reducing or non-reducing conditions and 
transferred onto PVDF-membrane (Invitrogen, Karlsruhe, Germany), using standard techniques. 
Briefly, the membrane was blocked with blocking buffer (PBS, 0.1% Tween 20, 2% skimmed milk) 
overnight at 4 °C and was then incubated with appropriately diluted primary antibody in blocking buffer 
for 1 h. After washing, the membrane was probed with biotinylated goat anti-mouse IgG, donkey anti-
chicken IgG or goat anti-rabbit IgG (Dianova, Hamburg, Germany), as appropriate, in blocking buffer 




Coupling of antibodies or streptavidin-phycoerythrin to fluorescent magnetic microspheres 
 
Six different sets of spectrally-unique, carboxylated magnetic 6.5 mm-microspheres were provided by 
Luminex Corp. (Austin, USA) for coupling of antibodies specific to ricin, abrin, SEB, BoNT/A, BoNT/B 
or the fluorescence quenching control streptavidin- phycoerythrin (SA-PE; Prozyme, San Leandro, CA, 
USA). Covalent coupling of the capture antibodies or SA-PE, alternatively, to the microspheres was 
performed according to manufacturer’s instructions (Bio-Plex Amine Coupling Kit, Bio-Rad 
  
Laboratories, Munich, Germany). Antibody sets of capture and biotinylated detection antibodies which 
gave optimal results for multiplex toxin detection are given in Table 1. 
 
 
Multiplex toxin detection 
 
All assays were carried out in a 96-well flat bottom microtiter plate (VWR International, Darmstadt, 
Germany) at room temperature, protected from light and shaken at 600 rpm. The multiplex assay was 
performed as follows: for each toxin to be analysed, 5000 antibody-labelled magnetic fluorescent 
microspheres, corresponding to selected bead regions (Table 1), were washed twice with PBS-T 
(PBS, 0.05% Tween 20) and were added to 50 mL of sample containing the indicated concentrations 
of toxins in either PBS-B (PBS, 1% BSA) or diverse food extracts, as specified in the text. The toxin–
microsphere-mixture was incubated for 2 h under shaking. Alternatively, for the enrichment 
experiments the bead–toxin-mixtures were incubated in a larger sample volume (500 mL) for 16 h, 
under rotation. After incubation the microspheres were transferred into a smaller assay volume of 50 
mL using a Dynal MPC-S magnet (Invitrogen, Karlsruhe, Germany). For automated washing and 
separation of the magnetic beads from the samples, a 96-well format magnet washer was used 
(hydroFLEX, Tecan, Crailsheim, Germany). The beads were washed twice with PBS-T and a cocktail 
of titrated biotinylated detection antibodies was added (100 mL/well, 1 h). The beads were washed as 
before and incubated with 4 mg/L SA-PE (100 mL/well) for 30 min. Following washing, the beads were 
resuspended in 125 mL PBS-B and the fluorescent signature of the beads and the corresponding 
PE-reporter signal was recorded using a Luminex system, in combination with the Bio-Plex Manager 
software (high calibration setting; Bio-Rad Laboratories, Munich, Germany). Routinely, 100 beads per 
region were measured in the 100 bead map with the DD-gates at 8000 and 22 000.  
 
 
Validation of the magnetic fluorescent bead array  
 
For statistical analysis, the limit of detection (LOD) was 
calculated by adding three standard deviations to the mean of the mean fluorescence intensities (MFI) 
of six blanks.  
 
Specificity was determined by measuring cross-reactivity to a number of related antigens at a fixed 
concentration in the upper plateau of the standard curves. At this concentration of the crossreactive 
antigen (Ccross), the apparent concentration of the analyte (Canalyte) was calculated from the 
measured MFI-value of the cross-reactive antigen, using the standard curve of the analyte. Reactivity 





To assess within- (intra) and between- (inter) run precision, we measured the standard curves for the 
5-plex assay at least 6 times over 3 days, with 2 replicates per concentration. The coefficient of 
variation (CV) equals the standard deviation divided by the mean for 6 values of a given concentration. 
 
 
Analysis of complex food samples  
 
Liquid or semisolid food samples (milk, iced coffee, carrot juice, baby food, yoghurt) were 
homogenised with an equal volume of gelatine-phosphate buffer (0.2% gelatine in 28 mM Na2HPO4, 
pH 6.2) using a BagMixer (Interscience, Saint Nom la Bretèche, France). After 1 h incubation under 
vigorous shaking the extracts were centrifuged, the supernatant 
was adjusted to pH 7.0 and 50 mL of the homogenate was spiked with the EC50 concentrations of 
ricin, abrin, SEB, BoNT/A, and BoNT/B derived from the multiplex toxin standard curves (see Fig. 1 
and Table 1; EC50 is defined as the half-maximum concentration that can be measured by the 5-plex 
suspension array for each analyte). Five thousand magnetic fluorescent microspheres labelled with 
the different capture antibodies and corresponding to the five different bead sets were added and the 
5-plex assay was performed as described above. As fluorescence quenching control, 5000 
microspheres coupled to SA-PE were incubated in an independent reaction for 2 h with the sample 
matrix or buffer as described above. After washing, the PE-reporter signal was determined in the 
Luminex system. For each of the five toxins spiked into food, the recovery rate of the observed amount 
  
of toxin compared to the expected known amount of toxin in the sample was expressed as a 
percentage. In the case of the fluorescence quenching control, the signal obtained in the complex food 
matrix was compared to the signal obtained in buffer and expressed as a percentage. 
 
 
Results and discussion 
 
Generation of antibodies against native toxins: a novel immunisation approach  
 
In order to circumvent the problem of high toxicity of proteotoxins in vivo we established a novel 
immunisation strategy for ricin, BoNT/A and BoNT/B. We covalently immobilised the native toxins onto 
2.8 mm-microbeads, in order to reduce toxicity. Exemplarily for ricin, we compared the toxicity of 
immobilised ricin versus free native ricin using a cell-culture cytotoxicity assay (Fig. 2A). Vero cells 
were treated with ricin or immobilised ricin at different concentrations and the concentration whereby 
50% of the cells survived after 24 h was determined (IC50). The immobilisation of ricin onto beads 
reduced its toxicity approximately 116-fold, from an IC50 of 0.6 mg/L (ricin) to 70 mg/L (ricin-beads). A 
significant eduction 
of toxicity was also seen for immobilised ricin in a mouse lethality test (data not shown). The toxin still 
showed residual toxicity, however, requiring careful titration prior to immunisation. Nevertheless, 
covalent coupling of the native toxin to microbeads enabled us to apply much higher antigen doses for 
immunisation than would have been possible for the free native toxin.  
 
The exact mechanism by which the reduction in toxicity is achieved is unknown. Covalent binding of 
ricin to the bead surface could occur via the A-chain, B-chain, or both, since the coupling process is 
not a directed process. We assume that the normal uptake of ricin into target cells via binding to sugar 
residues, and subsequent endocytosis (which is initiated via the B-chain), is substantially reduced for 
the immobilised toxin. It has been shown, however, that professional antigen-presenting cells, such as 
macrophages and dendritic cells, are able to phagocytose 3 mm-beads and are able to efficiently 
present bead-bound 
proteins to T- and B-cells, thus initiating a specific immune response.38 Particulate antigens have 
been found to be presented 1000-fold more efficiently on MHC class I and class II compared to soluble 
antigens.39–41 For different target molecules such as DNA, peptides, proteins and toxins, a variety of 
carriers have been successfully used for immunisation and vaccine development, e.g. gold or iron 
particles, nitrocellulose, virus-like particles, polystyrene or latex beads and biocompatible particles.42–
45  
 
Possible explanations for the residual toxicity of the immobilised ricin may be the following: if the 
covalent attachment to the bead surface occurred via the B-chain, the toxic A-chain could detach from 
the B-chain intracellularly and exert its functional activity. Furthermore, part of the native holo-toxin 
could stick on the bead surface via non-covalent binding forces and could detach upon application to 
cells in vitro or upon injection in vivo.  
 
 
Characterisation of toxin-specific antibodies  
 
In order to generate monoclonal (mAb) and polyclonal antibodies (pAb), we used covalently 
immobilised ricin, BoNT/A and BoNT/B to immunise mice, chickens and/or rabbits. The immobilised 
toxins were used either for the first immunisations followed by booster immunisations using free native 
toxins, or were used throughout the complete immunisation regimen (see Experimental section). For 
each toxin and each species separately, we tested the amount of immobilised toxin inducing a specific 
titer. This point is exemplarily demonstrated for one species and toxin in the Supplementary Data† 
(Table S2 and 
Fig. S1). It is worth mentioning that for the toxins and species analysed, we did not observe an 
increase in titer after switching from immobilised toxin to free native toxin (data not shown). 
 
In the case of ricin, the novel immunisation approach yielded 7 hybridoma clones and chicken IgY, 
which specifically recognised native ricin with high affinity. Table 2 summarises the characterisation of 
all mAb and pAb. Hybridoma clones R18 and R109 recognising the ricin A-chain or ricin B-chain, 
respectively, gave superior results in sandwich ELISA. Both hybridoma clones R18 and R109 
specifically reacted with ricin and the highly homologous R. communis agglutinin. They did not react 
with the closely-related plant toxin abrin, or with BoNT, SEB or BSA in an indirect ELISA (Fig. 2B and 
  
data not shown). In the case of BoNT/A and BoNT/B, the strategy of using immobilised BoNT/A and 
BoNT/B for immunisation yielded pAb of high quality in chickens and rabbits (Table 2). This approach 
did not work well, however, in mice as no significant titer emerged (data not shown). This might be due 
to a lower immunogenicity of BoNT in comparison to ricin. Therefore, we used the classical toxoid-
immunisation strategy in mice, with the extension that mice were boosted with the 50- to 250-fold 
half-maximal lethal dose (LD50) of native toxins, as soon as a toxoid-specific titer was detectable. 
Using this immunisation protocol, we obtained (among others) hybridoma A1688 specific for BoNT/A 
and hybridoma B755 specific for BoNT/B (Table 2). Both of these hybridomas exclusively reacted with 
their cognate antigen, but not with related BoNT serotypes, BSA (Fig. 2C), ricin, abrin or SEB (data not 
shown). Clones A1688 and B755 gave superior results in sandwich ELISA assays and were therefore 
used for further experiments. In the case of SEB, which is less toxic than the above-mentioned toxins, 
high quality mAb were produced after immunising with recombinant SEB. Among 70 positive 
hybridoma, clones S419 and S1001 were selected on the basis of their strong and selective 
recognition of SEB for further experiments (Fig. 2D).  
 
 
Multiplex toxin detection using a magnetic fluorescent suspension array  
 
As the main focus of the current work we implemented our antibodies against ricin (clones R109, 
R18), BoNT/A (clone A1688), BoNT/B (clone B755) and SEB (clones S419, S1001), along with 
commercially available reagents against abrin, into a magnetic and fluorescent suspension array 
suitable for the detection and quantification of the toxins from food. To this end, we used novel 
magnetic, spectrally-unique microspheres (6.5 mm diameter). First, we determined the optimal 
antibody pairs for single-toxin detection using titrations of the individual toxins in buffered solution. An 
antibody pair was considered optimal if it specifically detected its cognate antigen with high sensitivity, 
without cross-reacting with any other toxin. These optimal antibody pairs were combined for multiplex-
toxin detection (Table 1). The result of the multiplex optimisation process is presented in Fig. 1 and 
Table 3. Using the fluorescent magnetic suspension array for the analysis of a five-toxin-mixture in 
a sample volume of 50 mL, we obtained an LOD of 2 ng/L for ricin and 3 ng/L for SEB. In the case of 
BoNT/A and BoNT/B, a minimal amount of 21 ng/L and 73 ng/L, respectively, was detected. For abrin, 
the LOD was determined at 546 ng/L, (Fig. 1 and Table 3). For all five antigens investigated, the 
dynamic range of the assay spanned about three orders of magnitude of concentration above the LOD 
(Fig. 1).  
 
The antibody performance of the 5-plex magnetic fluorescent suspension array was compared with an 
amplified plate-bound single-toxin ELISA using the same antibody pairs as in the multiplex assay 
(ELISA: use of biotinylated secondary antibodies plus streptavidin-PolyHRP40; suspension array: 
detection using streptavidin-PE). For the four toxins, where we used our in-house reagents (ricin, SEB, 
BoNT/A, BoNT/B), we obtained similar standard curves and detection limits using the 
conventional single-toxin plate-bound ELISA and the 5-plex suspension array (Fig. 1 and Table 3). 
However, in the case of abrin, the plate-bound ELISA showed a lower detection limit, possibly due to 
more optimal reaction conditions and/or due to the amplification system used.  
 
One major advantage of the novel Luminex microbeads is that they can be used for immunomagnetic 
enrichment procedures. 
We investigated the 5-plex magnetic fluorescent bead array for enrichment of the toxins from a 500 
mL sample volume. Whilst the sample volume was increased 10-fold, the number of beads and the 
toxin concentrations were kept constant, compared to the standard 50 mL-reaction. In order to obtain 
ultimate sensitivity, the bead–toxin-mixtures were rotated for 16 h instead of 2 h. Under these 
conditions the maximal sensitivity was reached with an LOD of 0.3 ng/L for SEB, 4 ng/L for ricin, 6 
ng/L for BoNT/A, 24 ng/L for BoNT/B, and 85 ng/L for abrin (Table 3). For SEB, BoNT/A, BoNT/B and 
abrin the enrichment procedure resulted in a 3- to 10-fold improvement in sensitivity, while the ricin 
assay already gave maximal sensitivity using the standard protocol. Further increase of sample 
volume from 500 to 5000 mL, or an increase in incubation time (>16 h) did not significantly change the 
LOD for any of the five toxins analysed (data not shown).  
 
To our knowledge, there is no other multiplex detection system described which is able to detect five 
bacterial and plant toxins simultaneously from a minimal sample volume of 50–500 mL, in the low 
ng/L-range (compare Supplementary Table S1†). As an example several toxins, namely ricin, BoNT/A, 
BoNT/B and/or SEB, can be simultaneously detected using the NRL Array Biosensor,23,46 the 
bidiffractive grating  iosensor (BDG),47 the fiber optic fluorometer RAPTOR22 or the QTL 
biosensor.22 These systems offer the advantage of being portable, but are less sensitive with LODs in 
  
the low to medium mg/L-range. Their lower sensitivity is compensated for by a more rapid assay time 
(15 minutes compared to 3.5 hours for the magnetic fluorescent suspension array). While the different 
biosensors are optimised for assay time and portability, the focus of our work was to establish and 
validate a lab-based platform for highly sensitive detection of multiple toxins.  
 
It should be noted that some of the above-mentioned antibody- based detection systems detect BoNT 
toxoids instead of native toxins.23,25,48 In our experience, antibodies which recognise the toxoids do 
not usually bind the native toxins with high affinity. The development of antibodies which detect native 
toxins with high affinity is challenging, but necessary to obtain ultimate sensitivity.  
 
In order to improve sensitivity, Anderson and Taitt recently used the tyramide signal amplification 
strategy to detect toxins using the conventional (non-magnetic) Luminex technology: depending on the 
antigen analysed they were able to increase the sensitivity approximately 3- to 8-fold in a multiplex 
approach.25 For several toxins, however, the tyramide signal amplification failed or gave even weaker 
results (LODs for ricin 1 mg/L and for BoNT/A toxoid 10 mg/L).25 We also tested several amplification 
systems in order to further increase sensitivity (UltraAmp Multi- Assay Signal Amplifier, Genisphere, 
Hatfield, PA USA; Rolling circle amplification technology, Qiagen, Hamburg, Germany). However, 
using amplification systems in the current 5-plex magnetic fluorescent bead array resulted in a higher 
background fluorescence, without any beneficial effect on sensitivity (data not shown).  
 
Due to the principle of the Luminex xMAP technology, an increase in the number of microspheres 
used together with increased sample volume was not beneficial. The xMAP technology measures the 
mean MFI signal per bead set and an increase in the number of beads per sample lowers the total 
amount of analyte bound per bead. Conversely, a beneficial effect by lowering the number of beads 
and thereby increasing the amount of analyte per bead is limited by statistical considerations, as a 
suitable high number of beads must be analysed for a precise measurement.49  
 
 
Validation of the magnetic fluorescent suspension array 
 
As all five toxins are measured simultaneously, the specificity for each analyte is imperative. The 
specificity of the 5-plex magnetic fluorescent bead array was determined using 20 different antigens: 
different plant and animal lectins, closely-related staphylococcal toxins, different human pathogenic 
BoNT serotypes – either purified toxins or toxin complexes – and C. botulinum culture supernatants. In 
order to determine crossreactivity for all antigens a high concentration close to, or in the upper plateau 
of, the toxin’s standard curves was chosen (Table 4). All of the five toxins in our 5-plex assay were 
specifically detected with virtually no cross-reactivity to the other antigens. Ricin-beads detected ricin 
and weaker R. communis agglutinin which show about 90% sequence identity at the amino acid level. 
Among the staphylococcal enterotoxins SEC1 has the highest homology to SEB (67% on amino acid 
level) and is weakly detected by the SEB-beads (Table 4).  
 
The variability of the 5-plex assay was determined at three concentrations in buffered solution 
(standard 50 mL-reaction, 2 h incubation). For each of the toxins analysed, the mean withinrun 
precision was 5–10% (Table 5) and was therefore similar to within-run precisions reported for 
commercially available cytokine multiplex xMAP-assays, using conventional, non-magnetic beads.50 
The mean inter-assay precision values for all analytes 
(except ricin) were between 14 and 23% (Table 5). For ricin, we obtained a mean precision of 52%. 
Similarly, inter-assay precision values for different cytokines in commercial multiplex cytokine xMAP-
assays were reported to be optimally <25%, but single analytes showed higher between-assay values 
(>45%).50,51  
 




Analysis of complex food matrices  
 
BoNT/A, /B, /E and SEB have been isolated in food poisoning cases and ricin has been associated 
with accidental ingestions of castor beans in humans.53 With respect to potential bioterrorism attacks, 
one likely scenario focuses on toxins as water or food contaminants, especially food that is not heated 
before consumption. Pilot experiments showed that compared to nonmagnetic beads, magnetic beads 
offer the advantage of being easily separated from complex food matrices and the washing process 
  
can be automated. We therefore tested our 5-plex assay for the detection of the five toxins spiked into 
milk, iced coffee, 
carrot juice, baby food and yoghurt. For each toxin, the indicated food was spiked with the EC50 
concentration of the five toxins (Table 1) and recovery rates were determined. As shown in Fig. 3, the 
recovery rate of the observed amount of toxin compared to the expected known amount of toxin was 
between 50 and 100%. Baby food as a matrix gave poorer recovery rates of approximately 25% for 
BoNT/A and BoNT/B (Fig. 3). On the other hand, detection of ricin in carrot juice resulted in elevated 
recovery rates, approximately 150% (Fig. 3). Obviously, matrix effects appear to play a major role in 
assay performance, and this has also been observed by other groups.11,54,55 An obvious 
explanation might be that food components mask or even expose antibody-binding epitopes, thereby 
decreasing or increasing the analyte’s detection. Additionally, food components can also non-
specifically bind to an antibody, leading to elevated signals.  
 
Aside from matrix interference with antibody binding, apparently low recovery rates could be explained 
by the quenching of the reporter signal’s fluorescence by food components. Indeed, when we 
incubated in a separate reaction the food 
matrix or buffer with beads covalently coupled to SA-PE, we were able to estimate the fluorescence 
quenching effect due to the matrix components. Baby food as the matrix significantly quenched the 
SA-PE signal to 75%, indicating that the low recovery rate is mainly due to a fluorescence quenching 
effect (Fig. 3F). 
 
A major goal of this study was to assess the detection efficiency of the magnetic and fluorescent bead 
array for the simultaneous detection of toxins from food. If we take into account the human LD50 for 
ricin, abrin, BoNT/A and BoNT/B and the ED50 of SEB, we conclude that the assay is sufficiently 
sensitive to detect the afore-mentioned toxins far below the LD50 or ED50, respectively (Table 3). The 
LD50/ED50 values in Table 3 rely on estimated oral doses for humans56–60 calculated for a 10 kg 
toddler and a 100 mL serving of food. For all five toxins, there is at least a 2–3 orders of magnitude 
difference between the LOD in a 50 mL sample volume and the estimated oral LD50/ED50. It is 
important to note that even for the lower recovery rates obtained in the case of BoNT/A and BoNT/B in 
baby food, our assay sensitivity is sufficient to detect the five toxins below the lethal or effective doses 
(the spiked concentrations are already below the oral lethal doses, e.g. the spiked concentration 
EC50[BoNT/A] ¼ 700 ng/L, is approximately 140-fold less than the lethal dose for a 10 kg toddler and 





One major issue in the field of immunological detection of toxins is that high quality antibodies cannot 
be easily induced in experimental animals, since the native molecules are highly toxic for the animals. 
While it is relatively easy to produce antibodies against inactivated toxins, it is a challenge to generate 
antibodies which recognise the native molecules with high affinity. To our knowledge, this is the first 
study which describes the use of beadimmobilised native toxins for the immunisation of different 
species. The preparation of the antigen is rapid (<24 h) and high quality monoclonal and polyclonal 
antibodies can be obtained without expression of recombinant toxin sub-chains, chemical inactivation 
procedures or cloning of DNA expression vectors. The strategy might be useful for other highly toxic 
substances, provided that their immunogenicity in the selected laboratory animal is high enough. 
 
Using our antibodies along with commercially available reagents, we developed a magnetic and 
fluorescent bead array capable of simultaneously detecting five microbial and plant toxins not only in 
buffer, but also within complex food matrices. While a variety of biosensor technologies work well in 
the laboratory using buffered solutions, many technologies fail when targets are tested in complex 
matrices, most probably due to interference of matrix components with binding reagents or technical 
equipment. Using the magnetic and fluorescent bead array, we were able to detect ricin, abrin, 
BoNT/A, BoNT/B and SEB in the low ng/L-range from a minimal sample volume of 50–500 mL, which 
is superior to LODs obtained by other multiplex detection systems. The use of the novel magnetic and 
fluorescently-coded beads appears to be a major improvement of the conventional Luminex xMAP 
technology for three main reasons: First, enrichment procedures are now possible which result in a 
further improvement of sensitivity. Second, colloidal or particulate samples can now be analysed since 
the beadimmobilised target molecule can be easily separated from the matrix. And third, the washing 
process in a 96-well format can be automated, thus reducing the variability of the assay.  
 
  
As an open platform, the magnetic xMAP technology is ready for the implementation of up to 100 user-
specific antibody pairs. Since the magnetic and fluorescent antibody array is compatible with analysis 
of complex food matrices, it might be a useful tool for large-scale screening of the food supply chain. A 
further improvement in technology will be the introduction of a mobile device, allowing the step from a 
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Tables and Figures  
 











a EC50 is defined as the half-maximum concentration that can be measured by the 5-plex suspension 
array for each analyte (see later in Fig. 1). This concentration was used for spiking complex food 
matrices and recovery experiments (see later in Fig. 3). 
 
 
Table 2 Characterisation of anti-toxin antibodiesa 
 
  
a The signal strengths of the different antibodies in the indicated immunological assays are compared 
to the respective antibody yielding the highest signal in the technique used for a given toxin. The 
signal intensities are indicated on a relative scale: (-) corresponds to no signal; (+) corresponds 
to <25% relative signal intensity; (++) corresponds to 25–50% relative signal intensity; (+++) 
corresponds to 50–75% relative signal intensity and (++++) corresponds to >75% relative signal 
intensity. For in vitro blockade a yes (+)/no (-) response is indicated. n.d. ¼ not determined. 
 
 




a Shown is the comparison of the standard protocol of the 5-plex suspension array using 50 mL 
sample volume and microsphere–toxin-incubation for 2 h versus the enrichment protocol using 500 mL 
sample volume and 16 h incubation time. Data are from one exemplary experiment out of three 
(Bioplex) or two (ELISA). b The oral half-maximal lethal dose (LD50) of a toxin is the amount that kills 
50% of the animal test population after application per os. For our estimation, we assumed the oral 
LD50 for a 10 kg toddler to be present in a 100 mL serving of food. LD50 data are from refs 56–60. c 
For SEB, the effective dose (ED50) is used for the calculation. 
 
 




a The reactivity R of each bead set in the 5-plex assay was determined according to the formula given 
in the Experimental section and expressed on a relative scale, where (-) corresponds to R < 20%; (+) 
corresponds to R # 40%; (++) corresponds to R # 60%; (+++) corresponds to R # 80% and (++++) 









Table 5 Validation of 5-plex magnetic and fluorescent bead array: concentrations of analytes in 




a The CVs are reported as the within-assay/between-assay CVs for each validation sample above the 






Fig. 1 Detection of five toxins using a multiplexed magnetic and fluorescent suspension array 
compared to single-toxin detection via ELISA. In both methods, ricin (A), abrin (B), SEB (C), BoNT/A 
(D) and BoNT/B (E) were detected using the same capture and detection antibody pairs. The capture 
antibodies were either immobilised on magnetic and fluorescent microspheres (5-plex suspension 
array) or on microtiter plates (single-toxin ELISA). Different concentrations of toxins were added and 
the specific signal was detected either by incubation with a cocktail of biotinylated detection antibodies 
specific to all five antigens followed by SA-PE (5-plex suspension array) or by incubation with a single, 
corresponding biotinylated detection antibody and SA-PolyHRP (single-toxin ELISA). Given on the left 
is the mean fluorescent intensity (MFI) of the reporter signal measured by the Bio-Plex instrument and 






Fig. 2 Generation of toxin-specific antibodies. (A) Immobilised ricin is less toxic than native ricin. Using 
an in vitro cytotoxicity assay, Vero cells were incubated with different concentrations of native ricin or 
ricin immobilised on Dynabeads, respectively. The viability of the cells was quantified 24 h later using 
a cell proliferation assay as indicated in the Experimental section. (B–D) Specificity of novel mAb used 
for setting up the fluorescent and magnetic suspension array. (B) Using bead-immobilised ricin as 
antigen, a number of mAb were obtained (Table 2). mAb R18 and R109 were selected for further 
studies on the basis of their reactivity in ELISA-based assays. Shown are the results of an indirect 
ELISA where mAb R18 and R109 were tested against ricin, agglutinin, abrin and BSA (500 mg/L) 
immobilised on a microtiter plate. An anti-mouse peroxidase-labelled detection antibody was used for 
the detection of the specific signal. (C) mAb A1688 and B755 were obtained using a toxoid/toxin-
immunisation strategy. The mAb were tested in an indirect ELISA on different BoNT serotypes (/A, /B, 
/E, /F) or BSA, respectively. (D) mAb S419 and S1001 were obtained after immunising mice with 
recombinant SEB. The mAb were tested in an indirect ELISA on different staphylococcal enterotoxins 











Fig. 3 Multiplex toxin detection from complex food matrices using the 5-plex suspension array. The 
recovery rates of ricin (A), abrin (B), SEB (C), BoNT/A (D) and BoNT/B (E) from milk, iced coffee, 
carrot juice, baby food and yoghurt were determined. The food matrices were spiked with EC50 
concentrations of the toxin derived from multiplex standard curves (Fig. 1 and Table 1) and the 5-plex 
suspension array was performed as described in the Experimental section. (F) As a fluorescence 
quenching control, food matrices or buffer were incubated in a separate reaction with beads covalently 
coupled to SA-PE. The signal obtained in the complex food matrix was compared to the signal 
obtained in buffer and expressed as a percentage. 
  
